Condition: Progressive Multifocal Leucoencephalopathy (PML) · Sponsor: Hannover Medical School
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
This description comes directly from the study's public registry record.
Thomas Skripuletz, Prof. Dr. · +49 511 532 · skripuletz.thomas@mh-hannover.de
Always discuss trial participation with your own doctor first.
| LMU Klinikum Campus Großhadern | München, Bavaria, Germany | Not Yet Recruiting |
| Universitätsklinikum Marburg | Marburg, Hesse, Germany | Not Yet Recruiting |
| Hannover Medical School | Hanover, Lower Saxony, Germany | Recruiting |
| Universitätsklinikum Düsseldorf | Düsseldorf, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Universitätsklinikum Essen | Essen, North Rhine-Westphalia, Germany | Not Yet Recruiting |
| Universitätsklinikum Schleswig-Holstein | Kiel, Schleswig-Holstein, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06990087